Episode Details
Back to Episodes
Autolus Surges with AUCATZYL Momentum | Business and Finance News
Description
Autolus Therapeutics is on a rocket ship—Q2 2026 revenue for AUCATZYL jumped to $45.7M, nearly doubling from Q1, with H1 totals already nearing last year’s full-year haul. With over 80 U.S. treatment centers and physician buzz growing, the company raised its full-year revenue forecast to $140–150M, fueled by a soaring 55% gross margin thanks to scale and efficiency. Real-world data from TANDEM backs strong clinical outcomes, while expansion into the UK and ongoing trials for lupus, MS, and light-chain amyloidosis position Autolus for explosive growth—and potential launches in pediatric ALL and lupus nephritis down the line.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/4ec4ef17c6f88830